Distinct Features of Nonthyroidal Illness in Critically Ill Patients With Infectious Diseases

Woo Kyung Lee, MD, Sena Hwang, MD, PhD, Daham Kim, MD, Seul Gi Lee, MD, Seonhyang Jeong, BS, Mi-Youn Seol, MS, Hyunjee Kim, MS, Cheol Ryong Ku, MD, PhD, Dong Yeop Shin, MD, Woong Youn Chung, MD, PhD, Eun Jig Lee, MD, PhD, Jandee Lee, MD, PhD, and Young Suk Jo, MD, PhD

Abstract: Nonthyroidal illness (NTI), often observed in critically ill patients, arises through diverse alterations in the hypothalamic-pituitary-thyroid (HPT) axis. However, the causal relationship between underlying disease and NTI diversity in critically ill patients is poorly understood. The aim of this study was to examine NTI severity and adverse outcomes in critically ill patients with respect to their underlying disease(s).

The medical records of 616 patients admitted to the intensive care unit (ICU) between January 2009 and October 2014 were retrospectively reviewed. Patients with known diseases or taking medications that affect thyroid function were excluded. All-cause mortality (ACM) and length of stay (LOS) in the ICU were assessed as adverse outcomes.

The enrolled patients (n = 213) were divided into the following 4 groups according to the severity of NTI at the nadir of their thyroid function test (TFT): normal (n = 11, 5.2%), mild NTI (n = 113, 53.1%), moderate NTI (n = 78, 36.6%), and severe NTI (n = 11, 5.2%). There was no significant difference between the groups in terms of age and gender. NTI severity showed a significantly strong association with ACM (P < 0.0001) and a significant positive association with LOS in the ICU (P = 0.031). After adjusting for age, gender, and current medications affecting TFT, increasing NTI severity led to increased ACM (odds ratio = 3.101; 95% confidence interval = 1.711–5.618; P < 0.0001).

Notably, the prevalence of moderate-to-severe NTI was markedly higher in patients with infectious disease than in those with noninfectious disease (P = 0.012). Consistent with this, serum C-reactive protein levels were higher in patients with moderate-to-severe NTI (P = 0.016).

NTI severity is associated with increased ACM, LOS, and underlying infectious disease. Future studies will focus on the biological and clinical implications of infectious disease on the HPT axis.

INTRODUCTION

Nonthyroidal illness (NTI) syndrome, also known as “sick euthyroid syndrome” or “low T3 syndrome,” can be described as variations in the results of thyroid function tests (TFTs) in the absence of hypothalamic-pituitary and thyroid gland dysfunction. The early adaptive stage of NTI usually presents as low triiodothyronine (T3) or thyroxine (T4) levels, without an increase in thyrotropin (TSH). In a clinical setting, NTI is frequently observed in patients with acute or chronic critical illnesses who require treatment in the intensive care unit (ICU).1,2 However, the pathophysiology of NTI is unclear.

During the acute phase of critical illness (e.g., postsurgery or severe physical stress), circulating levels of T3 fall rapidly. These changes are generated by reduced levels of thyroid hormone binding proteins such as thyroxine binding globulin and albumin; thyroid hormone is easily released from thyroid hormone binding proteins due to a reduction in their binding affinity, leading to incremental increases in the clearance of thyroid hormone.3 In addition, alterations in the peripheral conversion of T4, mainly due to decreased type-1 deiodinase (D1) activity and increased type-3 deiodinase (D3) activity, induce the generation of reverse (r)T3.4,5 Although all these changes reduce circulating T3 levels, plasma TSH concentrations usually remain normal.4

During a prolonged phase of critical illness, central suppression of the hypothalamic-pituitary-thyroid (HPT) axis occurs.8 As hypothalamic stimulation of the pituitary thyrotropes diminishes, the production and release of thyroid hormones is further reduced; this can resemble central hypothyroidism, characterized by low plasma levels of unbound
T4 and/or low TSH concentrations. At this stage, pulsatile TSH secretion is almost abrogated. However, the mechanism underlying NTI progression from an adaptive response to a noncompensatory or maladaptive process that triggers hypothalamic suppression is poorly understood.

Recent studies suggest that cytokines such as tumor necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ), interleukin (IL)-1, and IL-6 are potential mediators of NTI. These cytokines directly downregulate various components of the thyroid hormone synthesis pathway at the thyrocyte level; however, no study has examined the role of cytokines in NTI progression in large human cohorts.

Because NTI in patients with a critical illness could be either adaptive or maladaptive, NTI during the acute phase of critical illness is beneficial; however, it may be deleterious during the prolonged phase. The latter interpretation stems from the observation that changes in plasma thyroid hormone levels are related to the risk of adverse outcomes. Here, we examined the correlation between NTI severity and adverse outcomes. In addition, we investigated NTI severity with respect to underlying disease.

METHODS

Study Population

The medical records of 616 patients admitted to the medical and surgical ICU at Severance Hospital, Yonsei College of Medicine (Seoul, South Korea) between January 2009 and October 2014 were retrospectively reviewed. All patients underwent a TFT (T3, T4, TSH) while being treated in the ICU. Of the 616 patients, 403 were excluded under the following exclusion criteria: patients with noncompensatory or maladaptive NTI were included in the study. Of these, 202 had normal thyroid function or NTI, and the other 202 had NTI, classed as mild (n = 113, 55.9%), moderate (n = 78, 38.6%), or severe (n = 11, 5.4%). There was no significant difference between the groups with respect to age and gender. As expected, NTI severity was closely related to T3, T4, and TSH values (P < 0.0001). In addition, NTI severity also correlated with serum total protein (P < 0.0001) and albumin (P = 0.002) levels.

The baseline characteristics of the 213 patients with normal thyroid function or NTI are listed in Table 1. Of these, 11 had normal thyroid function and the other 202 had NTI, classed as mild (n = 113, 55.9%), moderate (n = 78, 38.6%), or severe (n = 11, 5.4%). There was no significant difference between the groups with respect to age and gender. As expected, NTI severity was closely related to T3, T4, and TSH values (P < 0.0001). In addition, NTI severity also correlated with serum total protein (P < 0.0001) and albumin (P = 0.002) levels.

Association Between NTI Severity and Patient Outcome

We next examined the relationship between NTI severity and ACM and LOS. NTI severity was strongly associated with ACM (P < 0.0001; Figure 1A). In particular, ACM for patients with moderate or severe NTI was significantly higher than that for patients with mild NTI (P = 0.001; Figure 1A). LOS in the ICU was also related to NTI severity (P = 0.031; Figure 1B). To determine whether NTI is an independent risk factor for ACM, we used a multivariate logistic regression model adjusted for age, gender, and use of drugs that can affect thyroid function (such as dopaminergic, amiodarone, and steroids). Patients were split into 2 groups: Group I contained patients with normal or mild NTI, and Group II contained patients with moderate or severe NTI. According to model 1 (adjusted for age and gender), the risk of ACM was significantly higher in Group II [odds ratio (OR) = 3.519; 95% confidence interval (95% CI) = 1.975–6.271; P < 0.0001; Table 2]. According to model 2 (adjusted for age, gender, and the use of drugs that can affect thyroid function).
function, prescribed after ICU admission), the risk of ACM was again higher for Group II (OR = 3.101; 95% CI = 1.711–5.618; \( P < 0.0001 \); Table 2).

### NTI Severity and Infection

Because we observed a positive correlation between NTI severity and ACM and LOS, we next investigated the relationship between NTI and the underlying diseases that caused patients to be admitted to the ICU. NTI was more severe in patients with infectious diseases such as pneumonia and infections of nonlung origin (Table 3). To examine the effect of infection on NTI severity, we sorted the study patients into 2 groups: those with infectious disease and those with noninfectious disease (\( n = 75 \) and \( n = 138 \), respectively). There was a significant difference in CRP levels between those with infectious disease and those with noninfectious disease, indicating that the sorting was conducted appropriately (Supplementary Table 2, http://links.lww.com/MD/A888). The percentage of patients with moderate or severe NTI was significantly higher in the infectious disease group (\( P = 0.012 \)); in particular, severe NTI was only observed in the infectious disease group (Figure 2).

### Association Between NTI Severity and Acute Inflammatory Indices

To verify the relationship between NTI severity and infectious disease, we examined the relationship between NTI severity and acute inflammatory indices such as CRP levels and the ESR. CRP levels tended to increase according to NTI severity (\( P = 0.045 \); Figure 3A, upper panel). In addition, CRP levels were significantly higher in NTI group II than in NTI group I (\( P = 0.016 \); Figure 3A, lower panel). By contrast, there was no significant difference in ESR levels between the 2 groups. CRP levels in the infectious disease group also tended to increase with NTI severity, although the difference was not statistically significant (Supplementary Figure 1, http://links.lww.com/MD/A888). Finally, we performed bivariate correlation analysis to explore the correlation between thyroid hormone and CRP levels, and found that T3 levels negatively correlated with CRP levels (\( r = -0.199 \); \( P = 0.004 \); Figure 3B).

### DISCUSSION

This cohort study examined the association between NTI severity and patient outcome (ACM and LOS in the ICU). In addition, to understand the relationship between NTI severity and underlying disease, we also examined the etiology underlying NTI in our study patients. NTI severity was associated with an increased risk of an adverse outcome; the correlation remained statistically significant even after adjusting for iatrogenic drug interference. NTI was more severe in the group with infectious disease than in the group with noninfectious disease; moreover, CRP levels were significantly higher in those with more severe NTI. These findings suggest that NTI severity is an

---

**TABLE 1. Baseline Characteristics of the Study Population**

| Variable                  | Normal (\( n = 11 \)) | Mild NTI (\( n = 113 \)) | Moderate NTI (\( n = 78 \)) | Severe NTI (\( n = 11 \)) | \( P^* \) |
|---------------------------|-----------------------|------------------------|-----------------------------|------------------------|-----------|
| Age, y                    | 58.9 ± 17.4           | 69.1 ± 15.6            | 66.9 ± 15.2                  | 64.0 ± 14.2            | 0.155     |
| Gender, n (% female)      | 4 (36.4)              | 55 (48.7)              | 29 (37.2)                    | 5 (45.5)              | 0.437     |
| T3, ng/mL                 | 0.76 ± 0.13           | 0.38 ± 0.15            | 0.32 ± 0.18                  | 0.21 ± 0.17            | \(< 0.0001\) |
| fT4, ng/dL                | 1.12 ± 0.21           | 0.99 ± 0.19            | 0.94 ± 0.24                  | 0.56 ± 0.19            | \(< 0.0001\) |
| TSH, μIU/mL               | 1.55 ± 1.16           | 1.50 ± 1.06            | 0.40 ± 0.79                  | 0.11 ± 0.12            | \(< 0.0001\) |
| Total protein, g/dL       | 4.96 ± 0.99           | 4.52 ± 0.85            | 4.23 ± 0.80                  | 3.67 ± 0.48            | \(< 0.0001\) |
| Albumin, g/dL             | 2.51 ± 0.81           | 2.18 ± 0.40            | 2.11 ± 0.48                  | 1.78 ± 0.20            | 0.002     |

Data are expressed as mean ± SD or as n (%).

\( fT4 = \) free thyroxine, NTI = nonthyroidal illness, SD = standard deviation, T3 = triiodothyronine, TSH = thyroid-stimulating hormone.

*Continuous variables were analyzed using 1-way ANOVA and dichotomous variables were analyzed using Fisher’s exact test.

---

**FIGURE 1.** Relationship between NTI severity and patient outcome. (A) The severity of NTI was significantly associated with an increase in all-cause mortality (ACM). (B) The length of stay (LOS) in the ICU tended to be longer in the moderate-to-severe NTI group. The relationship between NTI severity and ACM and LOS was examined using the Chi-square test/Fisher’s exact test and 1-way ANOVA, respectively. Error bars represent the standard error. ICU = intensive care unit; NTI = nonthyroidal illness. *\( P = 0.001 \). **\( P \) for trend was 0.031.
independent risk factor for an adverse outcome for critically ill patients, and that infectious diseases play a role in the development of moderate-to-severe NTI. To the best of our knowledge, this is the first population-based cohort study to examine patient outcomes with respect to NTI severity, and the association between NTI severity and infection in critically ill patients.

NTI is an adaptive response that occurs during the acute phase of a critical illness; however, it can be deleterious during a prolonged critical illness. As mentioned previously, during the acute phase of a critical illness, circulating T3 levels fall rapidly, accompanied by an acute rise in rT3. These changes mainly result from changes in the circulation and peripheral organs such as reduced thyroid hormone binding and increased inactivation of thyroid hormones by type-3 deiodinases. Meanwhile, during the prolonged phase, central suppression of the HPT axis occurs. Here, we found that the more severe the NTI, the lower the total protein and albumin levels. Moreover, serum T3 levels were positively correlated with plasma protein and albumin levels (Supplementary Figure 2, http://links.lww.com/MD/A888). These results indicate that reduced thyroid hormone binding (due to reduced protein and albumin levels) plays a role in the development of NTI; this condition is probably persistent, even in cases of moderate or severe NTI involving hypothalamic suppression.

A few studies exploring the relationship between NTI and outcome in critically ill patients have been published.18,23–28 Two of these show that reduced fT4 levels are associated with mortality independently of TSH levels,25,27 whereas others found that T3 is a major predictor of survival.26,28 However, all of these studies were conducted on small numbers of selected patients. Here, we assessed thyroid function in 616 patients admitted to the ICU, and examined the association between NTI and outcomes in a final group of 202 patients with NTI; this is one of the largest cohorts reported to date. To minimize the effects of confounding factors, we excluded patients with underlying liver or renal diseases because these diseases can affect thyroid function directly by decreasing thyroid hormone binding capacity or changing clearance, which can make the severity of NTI worse than those caused by event-related

### TABLE 3. NTI Severity According to Underlying Disease

| Disease                  | Patients (n) | Gender (% Female) | Age, y | Normal, % | Mild NTI, % | Moderate NTI, % | Severe NTI, % |
|--------------------------|--------------|-------------------|--------|-----------|-------------|----------------|---------------|
| Pneumonia                | 79           | 39.2              | 69.4 ± 15.0 | 5.1       | 44.3        | 40.5           | 10.1          |
| Infection of nonlung origin | 59          | 47.5              | 63.9 ± 16.1 | 5.1       | 50.8        | 39.0           | 5.1           |
| Malignancy               | 18           | 44.4              | 66.8 ± 15.2 | 5.6       | 55.6        | 38.9           | 0             |
| Gastrointestinal disease | 5            | 60.0              | 76.0 ± 16.5 | 0         | 80.0        | 20.0           | 0             |
| Cardiac disease          | 3            | 0.0               | 74.0 ± 12.5 | 0         | 100         | 0              | 0             |
| Renal disease            | 6            | 50.0              | 76.7 ± 14.6 | 0         | 83.3        | 16.7           | 0             |
| Lung disease             | 8            | 75.0              | 73.4 ± 13.1 | 0         | 62.5        | 37.5           | 0             |
| Bleeding                 | 9            | 33.3              | 68.0 ± 15.0 | 0         | 55.6        | 44.4           | 0             |
| CNS disease              | 10           | 45.5              | 67.4 ± 15.5 | 0         | 70.0        | 30.0           | 0             |
| Transplantation          | 5            | 40.0              | 56.8 ± 17.0 | 0         | 40.0        | 60.0           | 0             |
| Other                    | 11           | 45.5              | 64.6 ± 17.0 | 27.3      | 63.6        | 9.1            | 0             |

CNS = central nervous system, NTI = nonthyroidal illness, SD = standard deviation.
*Data are expressed as means ± SD.
1Amyotrophic lateral sclerosis, aplastic anemia, autoimmune hepatitis, diabetic foot, diabetic ketoacidosis, previa totalis, postresuscitation status (n = 2), pyoderma gangrenosum, toxic epidermal necrolysis, and trauma.
Several studies show that NTI is associated with patient outcome in specific clinical settings. For example, Tognini et al reported that T3 levels are associated with short-term survival in a hospitalized older population, and Meuwese et al reported that fT3 levels were negatively associated with vascular calcification in patients with end-stage renal disease. However, these results are not generalizable to the association between NTI and critical illness. Furthermore, few studies have examined patient outcome according to NTI severity. Plikat et al reported that patients with low fT3 and fT4 levels had a higher mortality than patients with normal thyroid function and low fT3 levels. However, additional reductions in TSH levels, that is, severe NTI indicating central suppression of the HPT axis, did not affect patient outcome, including mortality. Here, we found that mortality was higher for patients with severe NTI (90.9%) than for those with mild or moderate NTI (37.2% and 61.5%, respectively), indicating that NTI severity is an important risk factor for an adverse outcome in critically ill patients.

Inflammatory cytokines are linked to the development of NTI. According to several studies, IL-1α and IL-1β inhibit both ¹²⁵I uptake and thyroid hormone secretion by human-cultured thyrocytes in the presence of TSH. IL-6 also inhibits TSH-induced increases in thyroid peroxidase mRNA expression and T3 release by thyrocytes obtained from patients with Graves’ disease. Furthermore, TNF-α and IFN-γ directly downregulate several components of the thyroid hormone synthesis pathway at the thyrocyte level. Also, thyroid hormone

![NTI severity in patients with infectious disease and noninfectious disease. NTI was significantly more severe in the patients with infectious disease than in those with noninfectious disease. Data were examined using Fisher’s exact test. NTI = nonthyroidal illness.](image1)

![Relationship between NTI severity and acute inflammatory indices. (A) The relationship between NTI severity and acute inflammatory indices in the entire cohort. CRP levels increased significantly with the severity of NTI. When CRP levels in patients with moderate and severe NTI were compared with those in patients with normal thyroid function or those with mild NTI, CRP levels were significantly higher in the former. However, there were no significant differences in ESR levels between the groups. (B) Correlation between T3 and CRP levels. T3 levels were inversely correlated with CRP levels (r = -0.199, P = 0.004). *P for trend was determined by 1-way ANOVA. A 2-sample t-test was conducted to compare acute inflammatory indices in the moderate and severe NTI group with those in the normal and mild NTI group. Pearson’s correlation coefficient was used for bivariate correlation analysis. Error bars represent the standard error. Data in the tables are expressed as means ± SD. CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; NTI = nonthyroidal illness; SD = standard deviation; T3 = triiodothyronine.](image2)
levels in an animal model fell after the administration of inflammatory cytokines.36 Accordingly, a few human studies describe a negative relationship between IL-6 and T3 levels.37–39 Consistent with these previous reports, we found that NTI is more severe in patients with infectious disease than in those with noninfectious disease, and that NTI severity is significantly associated with higher CRP levels, which are directly related to IL-6 levels.30 Moreover, T3 levels inversely correlated with CRP levels. However, this association lost significance when analyzing patients with infectious disease, although the trend was maintained. This might be because patients with infectious disease have worse liver function than patients with other diseases (possibly due to sepsis), which affects CRP levels.40 Overall, the present study supports the hypothesis that inflammatory cytokines, along with binding proteins and deiodinases, play a pivotal role in the development of NTI as well as in the crosstalk between NTI and infection.

There is much controversy surrounding the treatment of patients with NTI. Previous studies used animal models to examine the effect of treatment with thyroid hormones (T3 and T4) compared with treatment with releasing factors such as thyrotropin-releasing hormone (TRH) or growth hormone-releasing hormone (GHRH).41–43 These studies demonstrate that during a prolonged critical illness, treatment with T3 or T4 does not increase plasma thyroid hormone levels, whereas infusion of TRH increases plasma T3 and T4 levels. Furthermore, as the main cause aggravating NTI during a prolonged phase of critical illness is central suppression of the HPT axis rather than thyroidal capacity or changes in peripheral metabolism, treatment with hypothalamic-releasing factors such as TRH or GHRH may be better and more rational than treatment with thyroid hormones. However, few studies have investigated the effect of treatment with hypothalamic-releasing factors on patient outcomes in adequately powered, randomized controlled trials. With regard to treatment of NTI during an acute phase of critical illness, underlying diseases have been treated without thyroid hormone replacement therapy, as NTI is an adaptive response to reduce energy expenditure by lowering T3 levels.3

In conclusion, the severity of NTI is associated with adverse outcomes for critically ill patients, even after excluding confounding factors. Also, NTI is more severe in patients with infectious disease, possibly due to the presence of pro-inflammatory cytokines. Future studies should focus on the biological and clinical implications of infection with respect to the HPT axis. Furthermore, the outcomes of patients with infectious disease and moderate-to-severe NTI should be examined after treatment with hypothalamic-releasing factors.

REFERENCES

1. Boonen E, Van den Berge G. Endocrine responses to critical illness: novel insights and therapeutic implications. J Clin Endocrinol Metab. 2014;99:1569–1582.
2. Plikat K, Langgartner J, Buettner R, et al. Frequency and outcome of patients with nonthyroidal illness syndrome in a medical intensive care unit. Metabolism. 2007;56:239–244.
3. Van den Berge G. Non-thyroidal illness in the ICU: a syndrome with different faces. Thyroid. 2014;24:1456–1465.
4. Van den Berge GH. Acute and prolonged critical illness are two distinct neuroendocrine paradigms. Verh K Acad Geneeskd Belg. 1998;60:487–518.
5. Docter R, van Toor H, Krenning EP, et al. Free thyroxine assessed with three assays in sera of patients with nonthyroidal illness and of subjects with abnormal concentrations of thyroxine-binding proteins. Clin Chem. 1993;39:1668–1674.
6. Peeters RP, Wouters PJ, Kaptein E, et al. Reduced activation and increased inactivation of thyroid hormone in tissues of critically ill patients. J Clin Endocrinol Metab. 2003;88:3202–3211.
7. Rodriguez-Perez A, Palos-Paz F, Kaptein E, et al. Identification of molecular mechanisms related to nonthyroidal illness syndrome in skeletal muscle and adipose tissue from patients with septic shock. Clin Endocrinol (Oxf). 2008;68:821–827.
8. Mebis L, Van den Berge G. Thyroid axis function and dysfunction in critical illness. Best Pract Res Clin Endocrinol Metab. 2011;25:745–757.
9. Van den Berge G, de Zegher F, Veldhuis JD, et al. Thyrotrophin and prolactin release in prolonged critical illness: dynamics of spontaneous secretion and effects of growth hormone-secretagogues. Clin Endocrinol (Oxf). 1997;47:599–612.
10. Bartalena L, Bogazzi F, Brogioni S, et al. Role of cytokines in the pathogenesis of the euthyroid sick syndrome. Eur J Endocrinol. 1998;138:603–614.
11. Rasmussen AK, Kayser L, Feldt-Rasmussen U, et al. Influence of tumour necrosis factor-alpha, tumour necrosis factor-beta and interferon-gamma, separately and added together with interleukin-1 beta, on the function of cultured human thyroid cells. J Endocrinol. 1994;143:359–365.
12. Yamashita S, Kimura H, Ashizawa K, et al. Interleukin-1 inhibits thyrotropin-induced human thyroglobulin gene expression. J Endocrinol. 1989;124:177–183.
13. Nolte A, Bechtner G, Rafferzeder M, et al. Interleukin-1 beta (IL-1 beta) binds to intact porcine thyroid follicles, decreases iodide uptake but has no effect on cAMP formation or proliferation. Horm Metab Res. 1994;26:413–418.
14. Tominaga T, Yamashita S, Nagayama Y, et al. Interleukin 6 inhibits human thyroid peroxidase gene expression. Acta Endocrinol (Copenh). 1991;124:290–294.
15. Ahjan RA, Watson PF, Findlay C, et al. The sodium iodide symporter gene and its regulation by cytokines found in autoimmunity. J Endocrinol. 1998;158:351–358.
16. Tang KT, Braverman LE, DeVito WJ. Tumor necrosis factor-alpha and interferon-gamma modulate gene expression of type I 5'-deiodinase, thyroid peroxidase, and thyroglobulin in FRTL-5 rat thyroid cells. J Endocrinol. 1995;143:359–365.
17. De Groot LJ. Dangerous dogmas in medicine: the nonthyroidal illness syndrome. J Clin Endocrinol Metab. 1999;84:151–164.
18. Peeters RP, Wouters PJ, van Toor H, et al. Serum 3,3',5'-triiodothyronine (rT3) and 3,5,3'-triiodothyronine/T3 are prognostic markers in critically ill patients and are associated with postmortem tissue deiodinase activities. J Clin Endocrinol Metab. 2005;90:4559–4565.
19. Bello G, Pennisi MA, Montini L, et al. Nonthyroidal illness syndrome and prolonged mechanical ventilation in patients admitted to the ICU. *Chest*. 2009;135:1448–1454.

20. Tognini S, Marchini F, Dardano A, et al. Non-thyroidal illness syndrome and short-term survival in a hospitalised older population. *Age Ageing*. 2010;39:46–50.

21. Kim YA, Park YJ. Prevalence and risk factors of subclinical thyroid disease. *Endocrinol Metab*. 2014;29:20–29.

22. Melmed S, Polonsky KS, Larsen PR, et al. Williams Textbook of Endocrinology. *Elsevier Health Sciences*. 2011.

23. Leon-Sanz M, Lorente JA, Larrodera L, et al. Pituitary-thyroid function in critically ill patients as a predictor of high mortality. *Eur J Med Res.* 1997;2:477–482.

24. Silberman H, Eisenberg D, Ryan J, et al. The relation of thyroid indices in the critically ill patient to prognosis and nutritional factors. *Surg Gynecol Obstet.* 1988;166:223–228.

25. Slag MF, Morley JE, Elson MK, et al. Hypothyroxinemia in critically ill patients as a predictor of high mortality. *JAMA*. 1981;245:43–45.

26. Maldonado LS, Murata GH, Hershman JM, et al. Do thyroid function tests independently predict survival in the critically ill? *Thyroid*. 1992;2:119–123.

27. Van den Berge G, Baxter RC, Weekers F, et al. The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone. *Clin Endocrinol (Oxf).* 2002;56:655–669.

28. Loh KC, Eng PC. Prevalence and prognostic relevance of sick euthyroid syndrome in a medical intensive care unit. *Ann Acad Med Singapore*. 1995;24:802–806.

29. Anastasiou O, Sydor S, Sowa JP, et al. Higher thyroid-stimulating hormone, triiodothyronine and thyroxine values are associated with better outcome in acute liver failure. *PLoS One*. 2015;10:e0132189.

30. Meuwese CL, Glausson H, Qureshi AR, et al. Associations between thyroid hormones, calcification inhibitor levels and vascular calcification in end-stage renal disease. *PLoS One*. 2015;10:e0132353.

31. Han G, Ren J, Liu S, et al. Nonthyroidal illness syndrome in enterocutaneous fistulas. *Am J Surg*. 2013;206:386–392.

32. Yasar Z, Kirakli C, Cimen P, et al. Is non-thyroidal illness syndrome a predictor for prolonged weaning in intubated chronic obstructive pulmonary disease patients? *Int J Clin Exp Med*. 2015;8:10114–10121.

33. Sato K, Satoh T, Shizume K, et al. Inhibition of 125I organization and thyroid hormone release by interleukin-1, tumor necrosis factor-alpha, and interferon-gamma in human thyrocytes in suspension culture. *J Clin Endocrinol Metab*. 1990;70:1735–1743.

34. Nagayama Y, Izumi M, Ashizawa K, et al. Inhibitory effect of interferon-gamma on the response of human thyrocytes to thyrotropin (TSH) stimulation: relationship between the response to TSH and the expression of DR antigen. *J Clin Endocrinol Metab*. 1987;64:949–953.

35. Kung AW, Ma L, Lau KS. The role of interferon-gamma in lymphocytic thyroiditis: its functional and pathological effect on human thyrocytes in culture. *Clin Exp Immunol*. 1992;87:261–265.

36. Papanicolaou DA. Euthyroid Sick Syndrome and the role of cytokines. *Rev Endocr Metab Disord.* 2000;1:43–48.

37. Murai H, Murakami S, Ishida K, et al. Elevated serum interleukin-6 and decreased thyroid hormone levels in postoperative patients and effects of IL-6 on thyroid cell function in vitro. *Thyroid*. 1996;6:601–606.

38. Kimura T, Kanda T, Kotajima N, et al. Involvement of circulating interleukin-6 and its receptor in the development of euthyroid sick syndrome in patients with acute myocardial infarction. *Eur J Endocrinol*. 2000;143:179–184.

39. Abo-Zenah HA, Shoeb SA, Sabry AA, et al. Relating circulating thyroid hormone concentrations to serum interleukin-6 and -10 in association with non-thyroidal illnesses including chronic renal insufficiency. *BMC Endocr Disord.* 2008;8:1.

40. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. *J Clin Invest*. 2003;111:1805–1812.

41. Debaveye Y, Elliger B, Mebis L, et al. Tissue deiodinase activity during prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone-releasing peptide-2. *Endocrinology*. 2005;146:5604–5611.

42. Debaveye Y, Elliger B, Mebis L, et al. Regulation of tissue iodothyronine deiodinase activity in a model of prolonged critical illness. *Thyroid*. 2008;18:551–560.

43. Debaveye Y, Elliger B, Mebis L, et al. Effects of substitution and high-dose thyroid hormone therapy on deiodination, sulfoconjugation, and tissue thyroid hormone levels in prolonged critically ill rabbits. *Endocrinology*. 2008;149:4218–4228.